Vantage Health and Scripps Translational Science Institute form Strategic Partnership for Mobile Health Technology
February 10 2014 - 9:04AM
Business Wire
Vantage Health Inc. (OTCQB:VNTH) and its parent company Nanobeak
Inc. today announced that they have formed a strategic partnership
with Scripps Translational Science Institute (STSI) for the
advancement of mobile health technology.
Vantage Health is developing personalized and point-of-care
screening using Apps based upon chemical sensing residing within a
small device attached to a smartphone. STSI’s Center for Digital
Medicine is committed to helping in the development and research of
novel mobile health devices to accelerate their uptake into
clinical practice.
Through this strategic partnership, STSI will assist in the
testing, evaluation and detection of certain basic Volatile Organic
Compounds (VOCs) using Gas Chromatography and Mass Spectrometry to
calibrate the results of the Vantage sensor through validation.
STSI will also assist in the testing, evaluation and detection of
certain VOC’s commonly associated with Lung Cancer, using Gas
Chromatography and Mass Spectrometry to calibrate the results of
the Vantage sensor through validation.
STSI and Vantage Health will collaborate in the planning and
execution of clinical trials. The actual clinical trials are
expected to be carried out at STSI, as well as a 2nd location in
the Midwest and a 3rd location in New England.
STSI is a National Institutes of Health-sponsored consortium led
by Scripps Health in collaboration with The Scripps Research
Institute. Through this innovative partnership, STSI is leading the
effort to translate the latest wireless and genetic medical
technologies into high-quality, cost-effective treatments for
patients. Scripps Health is an integrated not-for-profit health
system based in San Diego with five hospital campuses and 26
outpatient clinics.
Commenting on today's announcement, Jeremy Barbera, chairman and
CEO of Vantage Health stated, “This is arguably one of the most
vital and exciting steps in our effort to transfer the technology
out of the labs at NASA and into the marketplace, as part of our
commercialization process. STSI’s Center for Digital Medicine,
under the leadership of STSI Director Eric Topol, M.D., and Scripps
Health digital medicine Director Steven Steinhubl, M.D., bring to
Vantage the expertise and clinical trial experience necessary to
successfully advance our mobile health applications.”
Dr. Steinhubl said, “This kind of collaboration is essential for
the testing and validation of wireless and mobile health
technologies. It offers the chance for transformational changes in
the way we diagnose and treat a wide range of conditions.”
About Vantage Health Inc.
Vantage Health Inc. - a leader in mobile health technology - is
developing personalized and point-of-care screening using Apps
based upon chemical sensing residing within a small device attached
to a smartphone.
With its foundations in advanced nanotechnology, the
company’s first product, the Vantage Health Sensor, is the
convergence of nano-electronics, bio-informatics, and wireless
technology to create the next generation mobile health application.
The first mobile App is expected to be for lung cancer
screening with additional mobile healthcare Apps in the planning
stages. The company has offices in Redwood City, CA and New York.
For more information, please visit
http://www.vantagehealthinc.com
About Scripps Translational Science Institute
Part of San Diego, Calif.-based Scripps Health, and the Scripps
Translational Science Institute (STSI) is a unique community
collaboration that initiates research that moves basic science from
the lab to the patient bedside. STSI is supported by the NIH
flagship program, Clinical and Translational Science Award (CTSA),
awarded to The Scripps Research Institute in conjunction with its
collaboration with STSI. The San Diego Supercomputer Center also is
a collaborator in the STSI consortium. More information can be
found at www.stsiweb.org.
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include, among other
things statements with respect to our objectives and strategies to
achieve those objectives, as well as statements with respect to our
beliefs, plans, expectations, anticipations, estimates or
intentions. Such forward-looking statements may also include
statements, among other things, concerning the efficacy, safety and
intended utilization of Vantage’s product candidates, the conduct
and results of future clinical trials, plans regarding regulatory
filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to
differ materially include, among others, the risk that product
candidates that appeared promising in early research and clinical
trials do not demonstrate safety and/or efficacy in larger-scale or
later clinical trials, trials may have difficulty enrolling,
Vantage may not obtain approval to market its product candidates,
or outside financing may not be available to meet capital
requirements. These forward-looking statements are based on our
current expectations. We caution that all forward-looking
information is inherently uncertain and actual results may differ
materially from the assumptions, estimates or expectations
reflected or contained in the forward-looking information, and that
actual future performance will be affected by a number of factors,
including economic conditions, technological change, regulatory
change and competitive factors, many of which are beyond our
control. Therefore, future events and results may vary
significantly from what we currently foresee.
For a further list and description of the risks and
uncertainties the Company faces, please refer to the Company’s most
recent Annual Report on Form 10-K and other periodic and other
filings Vantage files with the Securities and Exchange Commission
and are available at www.sec.gov. Such forward-looking statements
are current only as of the date they are made, and Vantage assumes
no obligation to update any forward-looking statements, whether as
a result of new information, future events or otherwise.
CSIR Group Investor RelationsChristine Petraglia,
212-386-7082Investors@csirgroup.com
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jul 2023 to Jul 2024